SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease. 1 "We are so grateful for the approval of SKYRIZI for ...

The FDA approved the TNF-alpha inhibitor golimumab (Simponi, Johnson & Johnson) to treat children with moderately to severely active ulcerative colitis (UC) weighing at least 15 kg. Of the more than 1 ...

Abdominal pain is prevalent in patients with active and quiescent ulcerative colitis (UC), affects a higher proportion of patients during active disease, and is worse among women, patients with ...

The FDA expanded the indications for guselkumab (Tremfya) to include adults with moderately to severely active ulcerative colitis, Johnson & Johnson announced on Wednesday. Approval of the dual-acting ...

Eli Lilly (NYSE:LLY) announced positive results from a late-stage trial of Omvoh (mirikizumab-mrkz) for patients suffering from moderately to severely active ulcerative colitis. The study demonstrated ...

Significantly more patients with moderately to severely active ulcerative colitis achieved clinical remission with the investigational monoclonal antibody tulisokibart compared with placebo, a ...

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation of the colon, and leads to symptoms such as fatigue, abdominal pain, and cramping. There is currently no cure ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative ...

Ease the symptoms of a UC flare, such as diarrhea, abdominal pain, and fever using expert-backed tips, and learn when to seek ...